Global Anti-Inflammatory Drugs Market Size to Reach USD 250.08 Billion in 2030 | Emergen Research

Potential pipeline candidates is a key factor driving anti-inflammatory drugs market revenue growth

Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) — The global anti-inflammatory drugs market size reached USD 111.42 Billion in 2021 and is expected to register a revenue CAGR of 9.3% during the forecast period, according to latest analysis by Emergen Research. Potential pipeline candidates is the main factor driving the market revenue growth.

For instance, the monoclonal antibody mirikizumab (LY3074828) fulfilled the primary and all significant secondary objectives in the LUCENT-1 ulcerative colitis Phase 3 study, according to a March announcement from Lilly. The drug’s potential as a therapy for moderate to severe ulcerative colitis was assessed throughout the 12-week multicenter induction phase.

Empower Your Decisions: Get the Sample Report Now @

The humanized monoclonal antibody attaches to the interleukin-23 p19 subunit (IL-23p19). A cytokine that promotes inflammation is interleukin-23. In March, Lilly bragged that the Phase 3 trial LUCENT-1, which used an anti-IL-23p19 monoclonal antibody, was the only one to show a reduction in bowel urgency in patients with moderate to severe ulcerative colitis. Mirikizumab can be used to treat ulcerative colitis and crohn’s disease, according to Lilly.

A recent trend in the market is the use of prodrug designing. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are a class of drugs that are among the most frequently used, prescribed, and over-the-counter (OTC) drugs for the treatment of inflammatory diseases. However, NSAIDs have several undesirable side effects, the most significant of which are ulcerogenicity, mucosal hemorrhage, and gastritis. The majority of NSAID moieties are chemically made up of carboxylic functional groups, which can be one of the causes of mucosal lining injury. The prodrug designing is one of the methods used to get around this problem. So, in the past ten years, medicinal chemists have focused a lot of their emphasis on designing and synthesizing NSAID prodrugs. The prodrug concept was developed to temporarily inhibit the free carboxylic group found in NSAIDs until their systemic absorption.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @

Scope of Research

Report Details Outcome
Market size in 2021 USD 111.42 Billion
CAGR (2022–2030) 9.3%
Revenue forecast to 2030 USD 250.08 Billion
Base year for estimation 2021
Historical data 2019–2020
Forecast period 2022–2030
Quantitative units Revenue in USD Billion and CAGR in % from 2022 to 2030
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Drug class, route of administration, Application, and region
Regional scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country scope U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, Rest of MEA
Key companies profiled AbbVie Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, Merck & Co., Inc., Pfizer Inc., Novartis AG, GSK plc, Lilly, Amgen Inc., Biogen
Customization scope 10 hours of free customization and expert consultation

Major Companies and Competitive Landscape

The global anti-inflammatory drugs market is fairly fragmented, with many large and medium-sized players accounting for a majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective anti-inflammatory drug solutions. Some major players included in the global anti-inflammatory drugs market report are:

  • AbbVie Inc.
  • Johnson & Johnson Private Limited
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis AG
  • GSK plc
  • Lilly
  • Amgen Inc.
  • Biogen

Strategic Development

  • On 18 August, 2022, Strides Pharma announced that the US Food and Drug Administration (USFDA) has given its Naproxen Sodium Softgel Capsules the go-ahead. A nonsteroidal anti-inflammatory medicine called naproxen sodium softgel capsules is used to treat pain or inflammation brought on by ailments including arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. Acute pain brought on by other disorders can also be treated with it. Naproxen Sodium Softgel Capsules have an estimated USD 100 million US OTC market.
  • On 22 August, 2022, the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for patent application by Baudax Bio, Inc., titled “Methods of administering intravenous meloxicam in a bolus dose,” which includes claims pertaining to the use of multiple doses of ANJESO for the treatment of moderate to severe pain that results in a decrease in summation.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @

Some Key Highlights From the Report

  • Anti-inflammatory biologics segment accounted for the largest revenue share in 2021. Before the body experiences or recognizes inflammatory signs, a number of metabolic steps take place. A biologic drug stops the inflammatory process in its tracks by directly targeting and inhibiting a specific reaction. Traditional drugs, in contrast to biologics, only treat general inflammation once it has begun (together with its accompanying symptoms, such as joint pain). When traditional NSAIDs (such as ibuprofen) or Disease-Modifying Antirheumatic Drugs (DMARDs) (such as methotrexate) are ineffective, patients with inflammatory autoimmune diseases including rheumatoid arthritis and ankylosing spondylitis can be prescribed biologic medicines. In addition to these traditional medications, biologics can be used. A biologic target is categorized based on where the inflammation is in the process.
  • Injection segment accounted for the largest revenue share in 2021. The market for anti-inflammatory biologics is anticipated to an increase in revenue as a result of the rising adoption of biologics. A special and effective type of medication known as a biologic that is given through injections reduces or stops dangerous inflammation. Biologics and biosimilars are specialized classes of DMARD. Usually, they are recommended after conventional DMARDs have failed. These powerful drugs are very effective in treating many individuals with autoimmune, and inflammatory arthritis, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and others. Since they are more challenging to produce than conventional DMARDs, they can be more expensive than many of the treatments an individual takes. While some medications can be provided via self-administered shots, others need Intravenous (IV) infusions performed in a doctor’s office.
  • Autoimmune inflammatory diseases segment accounted for the largest revenue share in 2021. The increased incidence of psoriasis, inflammatory bowel disorders, and rheumatoid arthritis all contribute to the growth of this segment. Globally, the prevalence of RA between 1980 and 2019 was 460 per 100,000 individuals, with regional differences related to research design and location. Up to 14 million instances of rheumatoid arthritis can exist globally, according to WHO. Psoriasis affects individuals of all ages and from all countries. According to estimates, psoriasis affects between 0.09% and 11.43% of the world’s population, making it a serious global problem that affects at least 100 million individuals. The World Psoriasis Day collaboration estimates that 125 million people globally, or 2 to 3% of the population, have psoriasis.
  • North America accounted for the largest revenue share in 2021 attributed to increasing initiatives to turn patients on to NSAIDs instead of opioids as they lead to addiction in this region. Dental pain is one example of this. Although Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are advised by the American Dental Association for pain management, opioids are nevertheless used more frequently than alternatives. However, more and more programmes are being launched to end this situation. NSAIDs that are prescribed include Advil (ibuprofen), Aleve (naproxen), and Celebrex (celecoxib). However, Rochester dentists claim that frequently, an individual’s medical history makes it impossible for them to be treated with NSAIDs. Following that, they employed a “multimodal” approach to pain management that included “NSAIDs, acetaminophen, and gabapentin.” This array of alternatives is supposed to fill the hole left when opioids are no longer used.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@

Emergen Research has segmented global anti-inflammatory drugs market on the basis of drug class, route of administration, application, and region:

  • Drug Class Outlook (Revenue, USD Billion; 2019-2030)
    • Anti-Inflammatory Biologics
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Corticosteroids
  • Route of Administration Outlook (Revenue, USD Billion; 2019-2030)
    • Oral
    • Injection
    • Inhalation
    • Topical
  • Application Outlook (Revenue, USD Billion; 2019-2030)
    • Autoimmune Inflammatory Diseases
      1. Rheumatoid Arthritis
      2. Psoriasis
      3. Others
    • Respiratory Diseases
    • Others
  • Regional Outlook (Revenue, USD Billion; 2019-2030)
    • North America
      1. U.S.
      2. Canada
      3. Mexico
    • Europe
      1. Germany
      2. France
      3. U.K.
      4. Italy
      5. Spain
      6. Benelux
      7. Rest of Europe
    • Asia Pacific
      1. China
      2. India
      3. Japan
      4. South Korea
      5. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • Middle East & Africa
      1. Saudi Arabia
      2. UAE
      3. South Africa
      4. Turkey
      5. Rest of MEA

Curated Reports You Shouldn’t Miss: Dive In Now!

Veterinary Ultrasound Market, By Type [Two-Dimensional (2D), Three-Dimensional/Four Dimensional (3D/4D), and Doppler], By Product, By Technology, By Animal Type, By Application, By End-Use, and By Region Forecast to 2030

Long Read Sequencing Market Size, Share, Trends, By Technology, By Products and Services (Kits and Assays, Systems, Software), By Application (Oncology, Infectious Diseases, Rare Diseases), By End Use, and By Region Forecast to 2028

Orthopedics Diagnostic Devices Market Size, Share, Trends, By Product (X-ray Systems, Fluoroscopy, Doppler Ultrasound, Others), By Type (Standalone and Point of Care), By Age Group, By Application, By End User, and By Region Forecast to 2030

Exosomes Market, By Type (Biomarkers, Drug Delivery Systems, Therapeutic Agents), By Product Type (Kits, Instruments & Reagents), By Application (Cancer, Neurodegenerative diseases, Infectious diseases, Others), By Region Forecast to 2030

Stool Softener Market, By Form (Medicines, Procedures), By Mode of Administration (Oral, Rectal), Availability (Over-the-Counter, Prescription), By End-Use (Hospitals, Clinics), and by Region Forecast to 2030

Synbiotics Market, By Form (Powdered, Liquid), By Application (Food & Beverages, Dairy, Pharmaceuticals, Aquaculture Farming), By Distribution Channel (Indirect, Direct), and By Region Forecast to 2030

Diabetic Socks Market, By Distribution Channel (E-Commerce, Retail Stores, and Hospital Pharmacies), By Material Type (Bamboo, Copper, Wool, Acrylic, Others), By Region Forecast to 2030

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:

Direct Line: +1 (604) 757-9756


Explore Our Japanese Version: Anti Inflammatory Drugs Market

Explore Our Blogs and Insights Section:

Read our Press Release @

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More